Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

2021/04/23 by Pragya D. Yadav, Gajanan Sapkal, Priya Abraham +10 · 3 citations
Medicine · Agricultural and Biological Sciences · #SARS-CoV-2 and COVID-19 Research #Animal Virus Infections Studies #Virology and Viral Diseases

paper · pdf · doi:10.1101/2021.04.23.441101

openalex publication_date 2021/04/23 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04

Abstract

Abstract The drastic rise in the number of cases in Maharashtra, India has created a matter of concern for public health experts. Twelve isolates of VUI lineage B.1.617 were propagated in VeroCCL81 cells and characterized. Convalescent sera of the COVID-19 cases and recipients of BBV152 (Covaxin) were able to neutralize VUI B.1.617.

Cited by

• A review of the safety and efficacy of current COVID-19 vaccines
• Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
• Variants of SARS-CoV-2 [wikipedia]

Related

• Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees
• Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
• Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2
• N440K variant of SARS-CoV-2 has Higher Infectious Fitness
• XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants